SoFi CEO enters prepaid forward contract on 1.5 million shares
Investing.com -- Shares of ALK-Abello A/S (CPH:ALK-B) climbed 2.5% as the company’s fourth-quarter sales came close to consensus estimates, despite a slight miss in gross profit.
The company’s earnings report indicated that fourth-quarter sales were only 1% shy of company consensus, with tablet sales exceeding expectations by 3%, which helped offset weaker performance in subcutaneous immunotherapy (SCIT)/sublingual immunotherapy (SLIT)-drops and other products.
The earnings before interest and taxes (EBIT) for the fourth quarter fell 22% behind consensus, mainly due to lower gross margin and higher sales, marketing, and administrative expenses. These total costs included one-off expenses related to European optimization initiatives and revisions to the company’s strategy in China.
Excluding these one-time costs, the capacity cost to revenue ratio was 48%, suggesting an adjusted EBIT of DKK240-245 million, which would be just 6%-8% behind consensus.
Looking ahead, ALK-Abello presented its revenue growth target for 2025, projecting a 9%-13% increase at constant exchange rates (CER), with consensus estimates hovering around the midpoint of this range. The company also reaffirmed its EBIT margin outlook at approximately 25%, aligning with broad consensus estimates.
The anticipated growth is expected to be driven primarily by double-digit percentage increases in tablet sales across all regions, attributed mainly to volume growth with a reduced impact from pricing and rebate adjustments compared to what was observed in 2024. Furthermore, the company expects a slight increase in gross margin.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.